Enlarge / A healthcare employee administers a dose of the Pfizer-BioNTech Covid-19 vaccine contained in the Viejas Area on the campus of San Diego State College in San Diego, California, US on Thursday, April 1, 2021. (credit score: Getty | Bloomberg)

In a small trial, the Pfizer/BioNtech vaccine totally protected individuals from symptomatic COVID-19 attributable to the worrisome B.1.351 coronavirus variant extensively circulating in South Africa, the businesses introduced in a press launch.

Although researchers will want extra knowledge to verify the outcome, it’s simply the newest little bit of constructive information to come back out this week about how the vaccines are performing with real-world circumstances and in real-world settings.

On Monday, the Facilities for Illness Management and Prevention launched real-world knowledge exhibiting that the Pfizer/BioNTech mRNA vaccine and Moderna mRNA vaccine had been, collectively, 90 p.c efficient at stopping infections in totally vaccinated well being care, frontline, and important employees.